Yikang Shi

Dr. Yikang Shi

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
XHXiqian Han
Xiqian Han
XZXiaobing Zhang
Xiaobing Zhang
HLHui Li
Hui Li
SHShengshi Huang
Shengshi Huang
SZShu Zhang
Shu Zhang
YSYikang Shi
Yikang Shi
Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo

14 September 2010 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
YSYikang Shi
Yikang Shi
ZLZhong-Hua Li
Zhong-Hua Li
XHXi-Qian Han
Xi-Qian Han
JYJi-Hu Yi
Ji-Hu Yi
ZWZhen-Hua Wang
Zhen-Hua Wang
PWPeng Wang
Peng Wang

4 August 2017 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SHShengshi Huang
Shengshi Huang
DWDi Wang
Di Wang
SZShu Zhang
Shu Zhang
XHXiaoyan Huang
Xiaoyan Huang
DWDandan Wang
Dandan Wang
YSYikang Shi
Yikang Shi

8 April 2021 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
DWDi Wang
Di Wang
JWJiaan Wu
Jiaan Wu
DWDandan Wang
Dandan Wang
XHXiaoyan Huang
Xiaoyan Huang
NZNaining Zhang
Naining Zhang
YSYikang Shi
Yikang Shi
O‑GlcNAcylation is a dynamic and reversible post‑translational modification of proteins that is modulated by O‑GlcNAc transferase (OGT) and O‑GlcNAcase (OGA). Alterations in the protein expression of O‑linked β‑N‑acetylglucosamine (O‑GlcNAc) can be induced by multiple factors. However, little is known of the effects of chemotherapeutic agents on O‑GlcNAcylation and the relevant molecular mechanisms in cancer cells. In the present study, to investigate whether cisplatin alters protein O‑GlcNAcylation and to explore whether protein O‑GlcNAc modification affects the antitumor activity of cisplatin, experiments were performed in vitro and in vivo. The results indicated that cisplatin treatment resulted in an enhancement of global protein O‑GlcNAc levels in the H1299, Hep G2 and MCF‑7 cells in vitro and in vivo. Cisplatin upregulated the protein and mRNA expression levels of OGT and OGA in H1299 cells. Moreover, cisplatin induced the significant enhancement of the enzymatic activity of OGT in H1299 cells. On the contrary, the activation of OGA decreased in response to cisplatin exposure in H1299 cells. Cisplatin inhibited the activity of AMP‑activated protein kinase (AMPK) by decreasing the AMP/ATP ratio. The present study also revealed that the decreased AMPK activation inhibited glutamine‑fructose‑6‑phosphate aminotransferase (isomerizing) 1 (GFAT1) phosphorylation and subsequently promoted the activity of GFAT1. Cisplatin‑induced GFAT1 activation elevated the production of the donor substrate, uridine 5‑diphospho‑N‑acetylglucosamine (UDP‑GlcNAc). However, alterations in the O‑GlcNAc levels by the inhibition of OGT and OGA did not affect the sensitivity of lung cancer cells to cisplatin. On the whole, the present study demonstrates that cisplatin enhances protein O‑GlcNAcylation by altering the activity of OGT, OGA and AMPK in vitro and in vivo.

17 October 2022 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JLJiaojiao Liu
Jiaojiao Liu
NZNaining Zhang
Naining Zhang
JWJiaan Wu
Jiaan Wu
PDPeng Dong
Peng Dong
HLHongshuai Lv
Hongshuai Lv
YSYikang Shi
Yikang Shi
Purpose: Most chemotherapeutic agents possess poor water solubility and show more significant accumulations in normal tissues than in tumor tissues, resulting in serious side effects. To this end, a novel dextran-based dual drug delivery system with high biodistribution ratio of tumors to normal tissues was developed. Methods: A bi-functionalized dextran was developed, and several negatively charged dextran-based dual conjugates containing two different types of drugs, docetaxel and docosahexaenoic acid (DTX and DHA, respectively) were synthesized. The structures of these conjugates were characterized using nuclear magnetic resonance and liquid chromatography/mass spectrometry (1H-NMR and LC/MS, respectively) analysis. Cell growth inhibition, apoptosis, cell cycle distribution, and cellular uptake were measured in vitro. Drug biodistribution and pharmacokinetics were investigated in mice bearing 4T1 tumors using LC/MS analysis. Drug biodistribution was also explored by in vivo imaging. The effects of these conjugates on tumor growth were evaluated in three mice models. Results: The dextran–docosahexaenoic acid (DHA)– docetaxel (DTX) conjugates caused a significant enhancement of DTX water solubility and improvement in pharmacokinetic characteristics. The optimized dextran–DHA–DTX conjugate A treatment produced a 2.1- to 15.5-fold increase in intra-tumoral DTX amounts for up to 96 h compared to parent DTX treatment. Meanwhile, the concentrations of DTX released from conjugate A in normal tissues were much lower than those of the parent DTX. This study demonstrated that DHA could lead to an improvement in the efficacy of the conjugates and that the conjugate with the shortest linker displayed more activity than conjugates with longer linkers. Moreover, conjugate A completely eradicated all MCF-7 xenograft tumors without causing any obvious side effects and totally outperformed both the conventional DTX formulation and Abraxane in mice. Conclusion: These dextran-based dual drug conjugates may represent an innovative tumor targeting drug delivery system that can selectively deliver anticancer agents to tumors.

1 December 2022 in Drug Delivery
Verified
Journal Article
Open access
PDPeng Dong
Peng Dong
HLHongshuai Lv
Hongshuai Lv
WJWeiping Jia
Weiping Jia
JLJiaojiao Liu
Jiaojiao Liu
SWSi Wang
Si Wang
YSYikang Shi
Yikang Shi
Most chemotherapeutic agents are nonspecific distribution and cause systemic toxicities. Polysaccharide-based conjugates are promising strategies to overcome these drawbacks. To this end, two synergistic drugs docetaxel (DTX) and docosahexaenoic acid (DHA) were independently covalently bonded through individual linkers to dextran (100 kDa) to produce a novel dual-drug conjugate dextran–DHA–DTX. The single-drug conjugates dextran–DHA and dextran–DTX were also prepared for comparison. Fluorescent dye Cy7.5-based conjugates dextran–Cy7.5 and dextran–DHA–Cy7.5 were synthesized for cellular uptake study. The dual-drug conjugate dextran–DHA–DTX self-assembled into nanoparticles with the diameter of 102.3 ± 8.3 nm and demonstrated enhanced water solubility and improved pharmacokinetic profiles. Cellular uptake results showed that the dual-drug conjugate entered cells more than the parent DTX by determining the intracellular DTX contents via HPLC/MS analysis and by determining the fluorescent intensity of dextran-Cy7.5 and dextran–DHA–Cy7.5. Importantly, the dual-drug conjugate dextran–DHA–DTX significantly accumulated in tumor tissues and dramatically reduced the DTX concentrations in normal tissues. The dual-drug conjugate completely eradicated all the MCF-7 xenograft tumors without obvious side effects and showed more superior antitumor activity than parent DTX and single-drug conjugate dextran–DTX and dextran–DHA. Both in vitro and in vivo studies showed that DHA enhanced the antitumor activity of dextran–DTX. The polysaccharide dextran-based dual-drug conjugates may represent an effective way to improve the chemotherapeutic agents.